Strategies for the management of hepatocellular carcinoma (Q36863488)

16 August 2017

1 reference

title

Strategies for the management of hepatocellular carcinoma (English)

1 reference

16 August 2017

Myron Schwartz

1

1 reference

16 August 2017

Sasan Roayaie

series ordinal

2

1 reference

16 August 2017

Manousos Konstadoulakis

series ordinal

3

1 reference

16 August 2017

language of work or name

1 reference

1 July 2007

1 reference

Nature Clinical Practice Oncology

16 August 2017

published in

1 reference

16 August 2017

volume

4

1 reference

16 August 2017

issue

7

1 reference

16 August 2017

page(s)

424-432

1 reference

Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

Rising incidence of hepatocellular carcinoma in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Relationship between hepatocellular carcinoma and cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-cyclohexanedione treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Hepatocellular carcinoma and sex hormones

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

The morphologic transition in hepatocellular carcinoma. A comparison of the individual histologic features disclosed by ultrasound-guided fine-needle biopsy with those of autopsy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Multimodal image-guided tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Targeting portal pressure measurements: a critical reappraisal.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Surgical results for hepatocellular carcinoma with macroscopic portal vein tumor thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

An analysis of 412 cases of hepatocellular carcinoma at a Western center

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Recurrent hepatocellular carcinoma after hepatic resection: prognostic factors and long-term outcome

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Liver transplantation for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Venous hemodynamics in living donor right lobe liver transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Toward the definition of immunosuppressive regimens with antitumor activity.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Impressive regression of primary liver cancer after treatment with sirolimus

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Hepatocellular carcinoma: is current therapy really altering outcome?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Kinase inhibition with BAY 43-9006 in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Transarterial chemoembolization alone and in combination with other therapies: a comparative study in an animal HCC model

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0844

7 January 2021

Identifiers

DOI

10.1038/NCPONC0844

1 reference

16 August 2017

1 reference